Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-11
2008-11-25
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S422000, C544S324000, C546S279100, C548S518000
Reexamination Certificate
active
07456190
ABSTRACT:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
REFERENCES:
patent: 6743791 (2004-06-01), Cao et al.
patent: 2004/0229875 (2004-11-01), Cao et al.
patent: 2006/0106069 (2006-05-01), Martinez-Botella et al.
patent: WO 02064586 (2002-08-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews 1996, vol. 96, pp. 3147-3176.
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews, 1996, vol. 96, pp. 3147-3176.
Brownlees, et al., “Tau Phosphorylation in Transgenic Mice Expressing Glycogen Synthase Kinase-3β Transgene”,NeuroReport, 8: 3251-3255, 1997.
Carmichael, et al., “Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation”,The Journal of Biological Chemistry, 277(37): 33791-33798, 2002.
Cohen, et al., “The Renaissance of GSK3”,Molecular Cell Biology, 2:769-776, 2001.
Cohen, et al., “Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action”,Twenty-Fourth Ciba Medal Lecture, 21: 555-567, 1993.
Cross, et al., “The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, But Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells Between Ras and Raf”,Biochem. J.303: 21-26, 1994.
Fabbro, et al., Protein Kinases as Targets for Anticancer Agents: From Inhibitors to Useful Drugs',Pharmacology&Therapeutics, 93: 79-98, 2002.
Kaytor, et al., “The GSK3β Signaling Cascade and Neurodegenerative Disease”,Current Opinion in Neurobiology, 12: 275-278, 2002.
Klein, et al., “A Molecular Mechanism for the Effect of Lithium on Development”,Proc. Natl. Acad. Sci. USA, 93: 8455-8459, 1996.
Massillon, et al., “Identification of the Glycogenic Compound 5-Iodotubercidin as a General Protein Kinase Inhibitor”,Biochem J.299: 123-128, 1994.
Phiel, et al., “GSK-3α Regulates Production of Alzheimer's Disease Amyloidβ Peptides”,Nature, 423: 435-439, 2003.
International Search Report issued for corresponding PCT application PCT/US2004/007540.
Aronov Alex
Hale Michael R.
Maltais Francois
Moon Young-Choon
Kosack Joseph R
Pearson Daniel A.
Shameem Golam M. M.
Vertex Pharmaceuticals Incorporated
LandOfFree
Compositions useful as protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions useful as protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions useful as protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4020922